Status:
COMPLETED
Serum Bio-markers in Pulmonary Hypertension
Lead Sponsor:
Papworth Hospital NHS Foundation Trust
Collaborating Sponsors:
Merck Sharp & Dohme LLC
Conditions:
Pulmonary Hypertension, Primary, 4
Eligibility:
All Genders
Brief Summary
Chronic thromboembolic pulmonary hypertension (CTEPH) is caused by scarred blood clots in the blood vessels supplying the lungs. This in turn leads to failure of the right side of the heart. The reaso...
Detailed Description
Chronic thromboembolic pulmonary hypertension (CTEPH) is an underdiagnosed form of pulmonary hypertension whose pathogenesis remains to be fully elucidated. Altered endothelial homeostasis, defective ...
Eligibility Criteria
Inclusion
- Patients able to give informed written consent
- Patients diagnosed with chronic thromboembolic pulmonary hypertension (CTEPH) according to international guidelines at an expert pulmonary hypertension centre
- Patients diagnosed with chronic thromboembolic disease (CTED) according to international guidelines at an expert pulmonary hypertension centre
- Age and sex matched healthy volunteers
Exclusion
- Patients with inflammatory comorbidities
- Patients taking immunosuppressant medication
Key Trial Info
Start Date :
April 4 2012
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 26 2017
Estimated Enrollment :
377 Patients enrolled
Trial Details
Trial ID
NCT04472533
Start Date
April 4 2012
End Date
October 26 2017
Last Update
July 15 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Royal Papworth Hospital NHS Foundation Trust
Cambridge, United Kingdom, CB2 0AY